We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Nestle To Help Bring Microbiome Therapeutic Products To Market

January 11, 2016: 12:00 AM EST
Nestlé announced it would participate in commercialization efforts for the Ecobiotics line of microbiome drugs being tested in clinical trials by Seres Therapeutics. Nestlé Health Science has purchased an equity stake in Seres (Cambridge, Mass.), which is developing the microbiome products for the treatment of Clostridium difficile bacterial infections of the digestive system, and for inflammatory bowel disease. The various products, based on microbial organisms, target the 100 trillion microorganisms that live within the human body. They are in different phases of human testing. C. diff infections are most common in people 65 years and older, and in immune-compromised patients treated with antibiotics for underlying infections.
"Nestlé Health Science Makes Latest Move In Breakthrough Microbiome Field", Nestlé Health Science, January 11, 2016, © Nestlé Health Science
Food & Nutrition
Other Food & Nutrition
North America
United States of America
Companies, Organizations
Innovation & New Ideas
Press Release
Products & Brands
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.